With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.
OBGYNs and the Provision of Sexual and Reproductive Health Care: Key Findings from a National Survey
This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that may return to the forefront of health policy discussions in the coming years.
The House Energy and Commerce Committee reconciliation proposal as part of the COVID relief package aims to encourage non-expansion states to take up the expansion by providing an additional temporary fiscal incentive for states to newly implement the ACA Medicaid expansion. This brief provides illustrative estimates of the net fiscal benefit to states from these incentives relative to state costs under the expansion.
This issue brief provides an overview of COVAX, the global mechanism to secure and deliver COVID-19 vaccines. The brief details COVAX’s organization, conditions for country participation, activities, and financing structure. Additionally, it looks at the history and remaining key issues of U.S. engagement with COVAX.
Here’s a breakdown of how states are including “high-risk medical conditions” in their vaccination priority groups. Among the 50 states and DC, 37 have provided explicit information on what conditions they consider “high risk.” Learn more in this Chart of the Week.Read More